Sarcoidosis of the skin D86.3

Author: Prof. Dr. med. Peter Altmeyer

Co-Autor: Hadrian Tran

All authors of this article

Last updated on: 11.11.2026

Dieser Artikel auf Deutsch

Synonym(s)

benigna lymphogranulomatosis; Benign lymphogranulomatosis; benign miliary lupoid; Besnier-Boeck-Schaumann disease; Besnier-Boeck-Schaumann M.; Boeck M.; Boeck's disease; Boeck's sarcoid; Cutaneous sarcoidosis; Cutaneous Sarcoidosis; miliary lupoid benignes; sarcoid boecksche; Sarcoidosis; Sarcoidosis cutaneous; Sarcoidosis cutaneous large-boned; Sarcoidosis cutaneous small nodules; Sarcoidosis subcutaneous nodular

History
This section has been translated automatically.

Jonathan Hutchinson 1875; Ernest Besnier 1889; Caesar Boeck, 1899

Definition
This section has been translated automatically.

Granulomatous, autoinflammatory multisystem disease of unknown etiology characterized by the occurrence of non-caseating epithelioid cellular granulomas of the skin (and other organs - see sarcoidosis below). Sarcoidosis can affect almost any organ system, with the lungs being the most commonly affected with a 95% frequency of involvement. The skin is affected in 30% of sarcoidosis cases.

The acronym TAGU stands for "tattoo-associated granulomas with uveitis" and refers to a rare, bilateral intraocular inflammation and concomitant development of sarcoid skin reactions in tattoo areas (Carvajal Bedoya G et al. 2020).

Sarcoidosis of the skin (9-37%) should be considered an integral part of the "systemic disease of sarcoidosis" with characteristic clinical and histological changes. It can occur at any time during the disease, but it is usually present at the onset of the disease. Sarcoidosis of the skin can present with or without systemic involvement. Approximately 60% of patients with sarcoidosis of the skin also have system involvement.

Because it is externally visible, cutaneous sarcoidosis is relatively easy to confirm clinically and biopsy.

The severity of integumentary involvement is determined less by functional limitations than by disturbances in the patient's external appearance.

You might also be interested in

Pharmacology-Toxicology
Advertisment

Classification
This section has been translated automatically.

Skin manifestations of sarcoidosis can be classified as follows:

  1. Macronodular form: (face, specifically the eyelids and nasolabial folds; special form: frostbite-likelupus pernio/angiolupoid—may involve bone and cartilage)
  2. Small-nodular disseminated form (most common form: face, extremities, trunk, mucous membranes)
  3. Plaque-like (disc-shaped, annular, extensive, or circinate) form ( clinically also appearing psoriasiform or ichthyosiform) 
  4. Subcutaneous nodular form (13% of patients): Nodules palpable beneath normal or slightly livid skin (Darier-Roussy)
  5. Ulcerative sarcoidosis: legs, ulcers without any other clinically significant morphological features
  6. Special forms:
    • Löfgren’s syndrome
    • Scar sarcoidosis (generally no systemic involvement expected; special form: sarcoidosis in tattoos; sarcoidosis in old scars or tattoos)
    • Angiolupoid
    • Lupus pernio
    • Mucosal sarcoidosis
    • Morphologically unusual variants: lichenoid, psoriasiform, verrucous, atrophic, or erythrodermic; “nail sarcoidosis” 

Occurrence/Epidemiology
This section has been translated automatically.

Incidence figures vary worldwide. The incidence for Caucasians (US data) is 10-14/100,000 inhabitants/year and for Americans of African descent 35-64/100,000 inhabitants/year. Sweden: 64/100.000 inhabitants/year; UK: 20/100.000 inhabitants/year; Spain and Japan: 1,4/100.000 inhabitants/year.

Etiopathogenesis
This section has been translated automatically.

Unexplained. Familial clustering is known. There is an association with HLA-B8, HLA-DBQ1, HLA-DR3B1. The latter two HLA subtypes appear to be associated with a good prognosis. Polymorphisms of the gene coding for angiotensin-converting enzyme(ACE gene) have been detected.

Excessive T-cell-mediated immune responses to an as yet undefined agent as well as autoimmunological or infectious genesis are being discussed. Environmental toxins and microbial pathogens are blamed as trigger factors for granuloma formation (Giner T et al. 2017). Among the microbial pathogens, mycobacteria, propionibacteria and herpes simplex viruses are repeatedly suspected.

Sarcoidosis leads to activation of CD4+ helper cells of the Th1 subtype. In bronchial lavage, a shift in the lymphocyte population of the CD4/CD8 ratio in favor of CD4+ cells could be detected (CD4/CD8 > 3.5 is highly specific).

As part of this inflammatory reaction, a large number of Th1 cytokines(IL-2, interferon gamma) are produced, which on the one hand initiate the sarcoid tissue reaction and on the other hand lead to B-cell stimulation and hypergammaglobulinemia.Monocytes are attracted from the peripheral blood via the production ofmonocyte chemotactic factor(MCF).

Manifestation
This section has been translated automatically.

Young women often fall ill. But all in all ♀ = ♂. First manifestation mostly between the ages of 20 and 40, less frequently in children. Biphasic course with maxima at 25-35 and 45-65 years of age.

Localization
This section has been translated automatically.

Predilection sites are the face (nose, forehead, cheeks), earlobes and the sides of the extremities. The bending sides of the arms are usually left free. The lesions typically occur in cool (reduced blood circulation) skin areas and in scars, mediastinal and peripheral lymph nodes, lungs, liver, spleen, eyes, parotis. Apart from the predilection sites, there is no particular distribution pattern, but the "disordered, random" occurrence of the lesions is typical of sarcoidosis of the skin.

Clinic
This section has been translated automatically.

Based on the clinical course, a distinction is made between:

  1. acute sarcoidosis (Löfgren's syndrome)
  2. subacute sarcoidosis
  3. chronic sarcoidosis

1. Acute sarcoidosis occurs in 5% of cases. It is defined by the triad of arthritis, bilateral adenopathy, and erythema nodosum. The presence of erythema nodosum often indicates a benign course with a tendency toward spontaneous resolution within 2 years. The presence of erythema nodosum is always associated with significant impairment of the patient’s general condition. 

Pulmonary changes are classified into 3 stages based on radiological criteria:

  1. Stage I: Bilateral lymph node enlargement
  2. Stage II: Parenchymal involvement
  3. Stage III: Fibrosis.

2.“Early-onset sarcoidosis”(EOS): A rare variant of acute sarcoidosis that manifests before the age of 5. It presents as a triad of symptoms consisting of a maculopapular rash, arthritis, and uveitis. Additional symptoms include fatigue, anorexia, fever, and hepatosplenomegaly. EOS usually occurs in isolation. A familial form is known as “Blau syndrome.”

3. Chronic sarcoidosis ( 95% of cases): A relapsing-remitting course, usually lasting for years, with involvement of the skin (15–35%), lungs (60% of patients), the lymphatic system (20%), liver (20%), eyes (18%), parotid glands (5%), lacrimal glands (see below regarding the rare Heerfordt syndrome), bones (osteitis multiplex cystoides of Jüngling), and joints (usually oligoarticular arthritis, primarily affecting the ankle joints). Flares are generally accompanied by significant impairment of cognitive function, fever, fatigue, and flu-like symptoms. 

The following skin manifestations of the chronic form are distinguished:

  • Maculonodular form: Brown or bluish-red, rough nodules and plaques larger than a plum, primarily on the nose, cheeks, and earlobes, as well as the extremities and trunk. Central regression is possible. Numerous telangiectasias. Diascopic examination reveals small-spotted or even extensive “lupoid” infiltrates; see also lupus pernio.
  • Small-nodular or papular disseminated form: Densely clustered, non-follicular, small reddish-brownish or bluish-reddish papules. Also small-nodular, possibly lichenoid lesions. Only minimal scaling. Extensive plaques that are clearly demarcated from the surrounding skin may form, with blurred, irregular borders. A lupoid infiltrate can be detected under diascopic examination. Later, hyperpigmentation and the development of telangiectasias occur. The extensor surfaces of the extremities, the trunk, and the face are affected. 
  • Annular or circinate form: Ring-shaped or confluent, irregularly shaped, sometimes extensive, brown or brown-red configurations of nodules or plaques with central atrophic regression.
  • Subcutaneous nodular form: Nodular, firm, painless lesions beneath skin that is normal in color or slightly livid.
  • Special forms:

Laboratory
This section has been translated automatically.

The laboratory findings listed below primarily pertain to acute sarcoidosis and sarcoidosis with systemic involvement. Isolated cutaneous sarcoidosis may present with completely normal laboratory parameters. The ESR may be elevated, the tuberculin test is usually negative, IgG is elevated in 50% of cases, and 1,25-OH-vitamin D3 is often elevated. Acute sarcoidosis:

  • ESR is always elevated!
  • Angiotensin-converting enzyme (ACE) (the enzyme responsible for converting angiotensin I into the vasoconstrictor angiotensin II) is elevated in approximately 60% of cases of acute sarcoidosis.
  • Neopterin may be elevated in up to 70% of cases (released by macrophages).
  • The soluble interleukin-2 receptor (sIL-2R, which reflects the degree of T-lymphocyte activation) is elevated in about 80% of cases involving systemic involvement. sIL-2R is the relevant laboratory parameter with the highest sensitivity. In the diagnosis of sarcoidosis, sIL-2R is the parameter of choice in addition to ACE due to its ease of measurement, stability, and high sensitivity (elevated levels are also seen in all T-cell-mediated diseases, e.g., chronic infections; hemoblastoses).
  • Chinatase-3-like protein ( YKL 40) correlates with the disease activity of sarcoidosis. The enzyme is a good marker for pulmonary sarcoidosis. 
  • Elevated gamma globulins and IgG (50%)
  • Hypercalcemia (15%)
  • Possible leukopenia and lymphopenia, as well as eosinophilia.

Histology
This section has been translated automatically.

Initially, there is loose nodular formation consisting of activated macrophages and epithelioid cells in the center, surrounded by dendritic cells. Grouped around the epithelioid cells are CD4-positive lymphocytes, which are encircled by CD8-positive lymphocytes. Central necrobiosis and fibrinoid swelling are rarely present (in contrast to infection-induced granulomatous reactions, such as tuberculosis, there is no caseous necrosis). As the granulomas persist, the number and density of epithelioid cells increase. Multinucleated giant cells of the Langhans and foreign-body types become increasingly prevalent. Hyalinization and fibrosis of the connective tissue also occur.

Healing occurs with scar formation.

Electron microscopy: asteroids (star-shaped inclusions in giant cells), birefringent substances, Schaumann inclusions (concentrically lamellar-layered inclusion bodies).

Diagnosis
This section has been translated automatically.

Sarcoidosis is diagnosed by exclusion and summation of various symptoms:

  • Clinic with diascopy (detection of the typical autoinfiltrate)
  • Skin biopsy (most important diagnostic criterion)
  • Ophthalmologic clarification: determination of the visual field to exclude ocular involvement.
  • Lymphopenia; the CD4/CD8 ratio is increased (sensitivity 0.70, specificity 0.83)17.
  • An- or hyperglycemia with recall antigens.
  • ANA is positive in 30% of patients.
  • ESR: elevated.
  • Eosinophilia: present in 25% of patients.
  • ACE level determination: marker of the "granuloma load" of the organism and elevated in about 60% of patients with systemic infestation; false positive results in about 10% of patients.
  • Note! ACE is suitable as a monitoring factor to determine progression.
  • Soluble IL-2 receptor level: elevated (expression of activated T lymphocytes).
  • Hypercalcemia (or hypercalciuria): detectable in 10% of patients. The cause is a production of 1,25-dihydroxy-vitamin D in mononuclear cells of the granulomas. This leads to increased intestinal Ca absorption. Determination of calcium in 24-hour urine required.
  • Chest X-ray: Lymph node swelling of the mediastinal or interstitial lymph nodes.
  • X-ray examination of the skeleton: Detection of bone cysts, especially in the finger and hand bones.
  • CT thorax: detection of granulomas, possibly evidence of pulmonary fibrosis.
  • Sonography of the liver.
Skin lesions and systemic involvement (modified according to Trebing and Göring)
Clinical form Systemic involvement
Lupus pernio/large nodular form

+++

Subcutaneous nodular form

+++

Cicatricial sarcoidosis

+++

Erythema nodosum

+++

Plaque form

++

Ulcerative form

++

Nodular form

+

Small nodular-disseminated form

+

"+" = hardly; "++" = rare; "+++" = frequent

Differential diagnosis
This section has been translated automatically.

Varies depending on the type of sarcoidosis, its stage of severity, and its location.

When located on the lower extremities: Necrobiosis lipoidica (Oppenheim-Urbach)

For annular plaques on the face: actinic granuloma

When annular plaques are present on the hands: Granuloma annulare

Granulomatous T-cell lymphomas of themycosis fungoides type

In lupus pernio: granulomatous rosacea

Additionally: Hodgkin’s disease; sarcoid skin reactions in lymphomas;foreign body granulomas (e.g., caused by silicon, beryllium, zirconium, lipids, cactus or sea urchin spines, plastic fibers); Leprosy tuberculoides, DISR (drug-induced sarcoid-like reactions, e.g., following administration of BRAF-MEK inhibitors)

Therapy
This section has been translated automatically.

The data situation for skin sarcoidosis is only moderately good due to the small number of cases in the mostly monocentric studies. Most studies have evidence levels of IIb, III and IV. Thus, all systemic therapeutics, including glucocorticosteroids, have an off-label use status. This means that the clinical expertise of the therapist is of particularly high importance.

External therapy
This section has been translated automatically.

Glucocorticoids are the mainstay of treatment. They are administered either as injections of triamcinolone (especially for nodular sarcoidosis, e.g., Volon A 10 crystal suspension diluted 1:1 with a local anesthetic such as Scandicain 1%), or—for plaque-like variants—as 0.05% clobetasol ointment (e.g.,Dermoxin®) applied under occlusion.

Long-term local corticosteroid therapy is not indicated for the facial area. In this scenario, off-label therapy with topical calcineurin inhibitors (tacrolimus, pimecrolimus) may be considered.  

Noteworthy are reports of the successful use of dithranol (NRF 11.51) in a petroleum jelly base (in increasing concentrations starting at 0.1% up to a maximum of 2%) with an application time of 20 minutes in each case. Regression of the sarcoid infiltrates in the skin was observed after 2–3 weeks (Darr-Foit S et al. 2020).   

Radiation therapy
This section has been translated automatically.

PUVA therapy can be tried; the success is limited. Note: Not a real alternative as the therapy would have to be followed consistently over a very long period of time (consequential damages have to be considered).

Internal therapy
This section has been translated automatically.

Given the generally favorable prognosis—with a high rate of spontaneous remission (60% of all Stage I pulmonary sarcoidosis cases resolve spontaneously)—and the relatively poor efficacy of existing systemic therapies, systemic therapy is indicated only under specific conditions.

Systemic therapy should be initiated in cases of disfiguring or cutaneous manifestations that do not resolve with topical therapy, as well as in cases of steroid-resistant changes in the fundus. Systemic treatment is also indicated for symptomatic lung disease, progressive or parenchymal lung disease after a 2-year course, persistent fever or weight loss, liver dysfunction, hepatosplenomegaly, lymphadenopathy, CNS involvement, hypercalcemia, myocardial involvement, myopathy, or myositis, as well as other serious organ involvement (e.g., kidneys).

First-line treatment:

  • Glucocorticoids (most effective systemic therapy):Prednisolone (e.g., Decortin H) initially 30–40 mg/day, tapered slowly over approximately 6 months.

Second-line treatment:

  • Antimalarial drugs, as well as immunosuppressants in combination with glucocorticoids; rarely used alone when glucocorticoids are contraindicated.
  • Chloroquine: Case reports indicate success with antimalarial drugs such as chloroquine (e.g., Resochin). Initial dose: 250 mg/day orally, then reduce to maintenance therapy with 250 mg orally twice weekly. Alternatively:  Hydroxychloroquine(e.g.,Quensyl®) 2–3 mg/kg body weight/day by mouth (considered better tolerated). Before and during therapy—ophthalmological follow-up!

Third-line treatment: 

  • Azathioprine (e.g., Imurek): 100 mg/day orally
  • Methotrexate (e.g., Lantarel): 15 mg/week by mouth or intramuscularly, with a gradual reduction to a maintenance dose of approximately 7.5 mg/week. A large 2-year study involving 50 patients demonstrated a steroid-sparing effect of MTX.
  • Mycophenolate mofetil (CellCept®): 500 mg 2-0-2. An alternative therapy that can be combined with corticosteroids (Kouba GJ et al. 2003) 

Experimental:

  • There are anecdotal reports regarding allopurinol (e.g., Zyloric) 300 mg/day,clofazimine (e.g., Lamprene) 200–400 mg/week, cyclosporine A (e.g., Sandimmun) 5 mg/kg body weight/day, orfumaric acid esters (e.g., Fumaderm 3–6 tablets Fumaderm® spread throughout the day) or low-dose fumarate therapy [Fumaderm® initial (90 mg/day dimethyl fumarate)] as long-term therapy. 
  • Biologics: Anecdotal reports and small studies with exceptionally good results exist regarding TNF-alpha inhibitors (etanercept,infliximab,adalimumab). In one study, combination therapy (etanercept 25 mg twice daily,prednisolone 30 mg once daily, hydroxychloroquine 200 mg twice daily, andmethotrexate 15 mg once weekly) (see also Giner T et al. 2019)

Operative therapie
This section has been translated automatically.

Cryosurgery can be attempted in frustrated attempts with topical glucocorticoids.

Progression/forecast
This section has been translated automatically.

Overall, more than 60% of sarcoidosis cases heal spontaneously within 2-5 years. 10-30% of cases are progressive.

Nodular and nodular sarcoidosis lesions are more likely to heal after months and years than plaques and lupus pernio (spontaneous healing possible in 50% of cases). Prognosis quoad vitam depending on pulmonary findings (development of pulmonary fibrosis).

Chronic cutaneous sarcoidosis: quoad sanationem poor. Risk factors for a chronic course are: age > 40 years, hypercalcemia, lupus pernio, chronic uveitis, cardiac or neurological involvement, pulmonary sarcoidosis stage III, symptom duration > 6 months, nephrocalcinosis.

Note(s)
This section has been translated automatically.

Name: Boeck coined the term sarcoidosis in 1899 and defined the disease as an entity.

Literature
This section has been translated automatically.

  1. Alexis A et al. (2005) Off-label dermatologic uses of anti-TNF-α therapies. J Cutan Med Surg 9: 296–302
  2. Bergner R et al. (2014) Immunosuppressive therapy for sarcoidosis. Akt Dermatol 40:325–340.
  3. Besnier E (1889) Lupus pernio of the face; symmetrical fungal (scrofulo-tuberculous) synovitis of the upper extremities. Annales de dermatologie et de syphilographie (Paris), 2nd series, 10: 333–336.
  4. Boeck CPM (1899) Multiple benign skin sarcoids. With 4 plates. (A previously undescribed skin condition. Norwegian Journal of Medical Science, Kristiania (Oslo) 60: 1321–1334.
  5. Brito-Zerón P et al. (2016) Epidemiological patterns of disease presentation in sarcoidosis: age, gender, and ethnicity-related differences. Clin Exp Rheumatol 34:380–388.
  6. Darr-Foit S et al. (2020) Disseminated cutaneous sarcoidosis with necrotizing granulomas and successful dithranol therapy in a 75-year-old patient. Akt Dermatol 46: 319–321.  
  7. Giner T et al. (2017) Sarcoidosis: A dermatological perspective on a rare multisystem disease. Hautarzt 68:526–535.
  8. Giner T et al. (2019) Sarcoidosis from a dermatological perspective. Akt Dermatol 45: 24–46.
  9. Haley H et al. (2004) Infliximab therapy for sarcoidosis (lupus pernio). Br J Dermatol 150: 146–149.
  10. Heffernan MP et al. (2006) Adalimumab for the treatment of cutaneous sarcoidosis. Arch Dermatol 142: 17–23
  11. Howard A, White CR (2003) Non-infectious granulomas. In: Bologna JL et al. (eds.) Dermatology, Mosby, London, New York, Toronto, pp. 1455–1469
  12. Hutchinson J (1877) Case of livid papillary psoriasis. In: Illustrations of Clinical Surgery. Vol. 1, J and A Churchill, London, p. 42.
  13. Kouba DJ et al. (2003) Mycophenolate mofetil for the treatment of sarcoidosis. Dr. J. Dermatol. 148: 147–148 
  14. Manalo IF et al. (2016) More immune dysregulation: Sarcoidosis and chronic graft-versus-host disease after allogeneic stem cell transplant. JAAD Case Rep 2:138–140.
  15. Pfeiff B et al. (1986) Cutaneous sarcoidosis. Z Hautkr 61: 1311–1317.
  16. Reddy SB et al. (2017). Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma. J Immunother 40:307–311. 
  17. Tenneson, H; Quinquaud, CE (1892) Lupus pernio. Annales de Dermatologie et de Syphiligraphie (Paris) 3: 142–144.
  18. Shen Yongchun et al. (2016) “Diagnostic Performance of the Bronchoalveolar Lavage Fluid CD4/CD8 Ratio for Sarcoidosis: A Meta-Analysis.” EBioMedicine 8: 302–308.
  19. Zouboulis CC (2021) Long-term low-dose fumaric acid ester therapy for treatment-resistant cutaneous sarcoidosis. Hautarzt 72: 909–912. 

Disclaimer

Please ask your physician for a reliable diagnosis. This website is only meant as a reference.

Authors

Last updated on: 11.11.2026